BiomX – executive interview

Published on 12 August 2020

BiomX (NYSE: PHGE) is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as bacteria that affect the appearance of the skin. Phage is a form of virus which attacks only bacteria. BiomX discovers and validates proprietary bacterial targets and customizes its natural and engineered phage compositions against these targets.

In our Israel office, EdisonTV interviews BiomX chief executive officer, Jonathan Solomon, providing us with an introduction to the company and an update on its progress.

Share this with friends and colleagues